Journal article

Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study

Mathias Due Buron, Tomas Kalincik, Finn Sellebjerg, Per Soelberg Sorensen, Melinda Magyari

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | BMJ PUBLISHING GROUP | Published : 2021

Abstract

BACKGROUND: Switching between first-line disease-modifying therapies in patients with clinically stable relapsing-remitting multiple sclerosis (RRMS) due to reasons other than disease activity is frequent, but evidence on the effect of this practice is limited. We investigated the effect of switching patients with stable RRMS on occurrences of disability accumulation, relapses and future treatment discontinuation. METHODS: Using the Danish Multiple Sclerosis Registry, we identified patients with RRMS without disease activity who either (1) stayed on injectable platform therapy (interferon-β or glatiramer acetate) or (2) switched to dimethyl fumarate (DMF) or teriflunomide (TFL) and compared ..

View full abstract